izpis_h1_title_alt

Applicability of RPMI 2650 and Calu-3 cell models for evaluation of nasal formulations
ID Sibinovska, Nadica (Author), ID Žakelj, Simon (Author), ID Trontelj, Jurij (Author), ID Kristan, Katja (Author)

.pdfPDF - Presentation file, Download (689,95 KB)
MD5: A79BDF1F302D32E68B3BFC348C76664A
URLURL - Source URL, Visit https://www.mdpi.com/1999-4923/14/2/369 This link opens in a new window

Abstract
The RPMI 2650 and Calu-3 cell lines have been previously evaluated as models of the nasal and airway epithelial barrier, and they have demonstrated the potential to be used in drug permeation studies. However, limited data exist on the utilization of these two cell models for the assessment of nasal formulations. In our study, we tested these cell lines for the evaluation of in vitro permeation of intranasally administered drugs having a local and systemic effect from different solution- and suspension-based formulations to observe how the effects of formulations reflect on the measured in vitro drug permeability. Both models were shown to be sufficiently discriminative and able to reveal the effect of formulation compositions on drug permeability, as they demonstrated differences in the in vitro drug permeation comparable to the in vivo bioavailability. Good correlation with the available bioavailability data was also established for a limited number of drugs formulated as intranasal solutions. The investigated cell lines can be applied to the evaluation of in vitro permeation of intranasally administered drugs with a local and systemic effect from solution- and suspension-based formulations.

Language:English
Keywords:RPMI 2650 cell line, Calu-3 cell line, nasal drug formulations, nasal epithelium, drug permeability
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2022
Number of pages:19 str.
Numbering:Vol. 14, iss. 2, art. 369
PID:20.500.12556/RUL-137348 This link opens in a new window
UDC:615
ISSN on article:1999-4923
DOI:10.3390/pharmaceutics14020369 This link opens in a new window
COBISS.SI-ID:107048707 This link opens in a new window
Publication date in RUL:13.06.2022
Views:722
Downloads:106
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Pharmaceutics
Shortened title:Pharmaceutics
Publisher:MDPI
ISSN:1999-4923
COBISS.SI-ID:517949977 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:06.02.2022

Projects

Funder:Other - Other funder or multiple funders
Funding programme:Lek Pharmaceuticals, d.d., Sandoz Development Center Slovenia

Funder:ARRS - Slovenian Research Agency
Project number:P1-0189
Name:Farmacevtska tehnologija: od dostavnih sistemov učinkovin do terapijskih izidov zdravil pri otrocih in starostnikih

Funder:Other - Other funder or multiple funders
Funding programme:Public Scholarship, Development, Disability and Maintenance Fund of the Republic of Slovenia

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back